Benactyzine

Identification

Name
Benactyzine
Accession Number
DB09023
Type
Small Molecule
Groups
Withdrawn
Description

Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.

Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Cedad / Cevanol / Deprol / Lucidil / Morcain / Nutinal / Parasan / Phebex / Phobex / Suavitil (Merck)
Categories
UNII
595EG71R3F
CAS number
302-40-9
Weight
Average: 327.4174
Monoisotopic: 327.183443671
Chemical Formula
C20H25NO3
InChI Key
IVQOFBKHQCTVQV-UHFFFAOYSA-N
InChI
InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate
SMILES
CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Benactyzine.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Benactyzine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Benactyzine is combined with Atracurium.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Benactyzine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Benactyzine.Approved, Vet Approved
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Benactyzine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Benactyzine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Benactyzine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Benactyzine.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Benactyzine.Experimental
Botulinum Toxin Type ABenactyzine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BBenactyzine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Benactyzine is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Benactyzine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Benactyzine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Benactyzine.Approved
CimetropiumBenactyzine may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Benactyzine.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Benactyzine.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Benactyzine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benactyzine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Benactyzine.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Benactyzine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Benactyzine is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Benactyzine is combined with DPDPE.Investigational
DronabinolBenactyzine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Edrophonium.Approved
EluxadolineBenactyzine may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Benactyzine is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Benactyzine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Benactyzine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Benactyzine.Approved
GalantamineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Benactyzine.Approved
Ginkgo bilobaThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Benactyzine is combined with Glucagon recombinant.Approved
GlycopyrroniumBenactyzine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Benactyzine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Benactyzine.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Benactyzine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Benactyzine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Benactyzine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Benactyzine.Approved
IpidacrineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Benactyzine.Approved
IsoflurophateThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Benactyzine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Benactyzine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Benactyzine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Benactyzine.Approved
MefloquineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Benactyzine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Benactyzine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Benactyzine.Approved
Methyl salicylateThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MetixeneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Benactyzine.Approved
MianserinMianserin may increase the anticholinergic activities of Benactyzine.Approved
MinaprineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Benactyzine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Morphine.Approved, Investigational
NabiloneBenactyzine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Benactyzine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Benactyzine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Benactyzine is combined with Otilonium.Experimental
OxitropiumThe risk or severity of adverse effects can be increased when Benactyzine is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Benactyzine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Benactyzine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Benactyzine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Benactyzine.Approved
ParaoxonThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Benactyzine.Approved
PethidineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Benactyzine.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Benactyzine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Benactyzine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Benactyzine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Benactyzine.Approved
Potassium ChlorideBenactyzine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Benactyzine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Benactyzine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Benactyzine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Benactyzine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Benactyzine.Approved
RamosetronBenactyzine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Benactyzine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benactyzine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Benactyzine is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Benactyzine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Benactyzine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Benactyzine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Benactyzine.Approved
TacrineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tilidine.Experimental
TiotropiumBenactyzine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Benactyzine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Benactyzine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Benactyzine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Benactyzine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Benactyzine.Approved
TropatepineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Benactyzine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Benactyzine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Benactyzine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Benactyzine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Benactyzine.Approved
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,394,770.

General References
  1. McLaughlin B, Rickels K, Abidi M, Toro R: Meprobamate-benactyzine (Deprol) and placebo in two depressed outpatient populations. Psychosomatics. 1969 Mar-Apr;10(2):73-81. [PubMed:4891208 ]
External Links
KEGG Drug
D07498
PubChem Compound
9330
PubChem Substance
310264979
ChemSpider
8966
BindingDB
50144504
ChEBI
94775
ChEMBL
CHEMBL70352
Drugs.com
Drugs.com Drug Page
Wikipedia
Benactyzine
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)177-178 (Hydrochloride salt)U.S. Patent 2,394,770.
Predicted Properties
PropertyValueSource
Water Solubility0.188 mg/mLALOGPS
logP3.45ALOGPS
logP3.44ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)11.05ChemAxon
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity95.77 m3·mol-1ChemAxon
Polarizability36.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0309000000-31b1e744376b7dab1f25

Taxonomy

Description
This compound belongs to the class of chemical entities known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Benzenoids
Sub Class
Benzene and substituted derivatives
Direct Parent
Diphenylmethanes
Alternative Parents
Tertiary alcohols / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
Substituents
Diphenylmethane / Tertiary alcohol / Amino acid or derivatives / Carboxylic acid ester / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid derivative / Monocarboxylic acid or derivatives / Alcohol / Aromatic alcohol
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 25, 2014 11:30 / Updated on October 02, 2017 06:12